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Background: Gastric leak after laparoscopic sleeve gastrectomy (LSG) is a serious complication. Currently,
the literature lacks long-term outcomes in LSG and leak rates after reinforcement of the staple line. The
aims are two-fold: to present leak rates from using staple line reinforcement and six year outcomes of
LSG in relation to resolution of obesity-related comorbidities and long-term weight loss.
Materials and methods: This is a single-institution, retrospectively reviewed study of 204 patient case
ﬁles. Data from all patients undergoing LSG between December 2007 and May 2013 was collected.
Results: The total complication rate was 6.9% (14/204), with no recorded staple line leaks. The mean
postoperative Body Mass Index (BMI) at 1 year, 2 years, 3 years, 4 years, 5 years, and 6 years was 39.3 ± 8,
38.7 ± 8, 40.4 ± 9, 40.5 ± 10, 43.0 ± 10, and 42.4 ± 7, respectively. The mean % excess weight loss at 1 year,
3 years, and 6 years was 48.4 ± 19, 51.7 ± 28, and 41.0 ± 21, respectively. There were no signiﬁcant
differences between follow-ups at year 1 and 3 (p > 0.05), and between year 3 and 6 (p > 0.05) for the
mean % excess weight loss. The resolution rates for all patients were 74%, 61%, 79%, and 90% for hy-
pertension, hypercholesterolemia, diabetes mellitus type 2 and obstructive sleep apnea, respectively.
Conclusion: The synthetic bioabsorbable reinforcement material shows no staple line leaks making it
safe to use. LSG as a procedure had a high resolution of obesity-related comorbidities as well as sus-
tainable long-term weight loss.
© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since 2003, laparoscopic sleeve gastrectomy (LSG) has been
rising in popularity in Europe, increasing to 127 ofﬁcially docu-
mented operations in 2007 [1,2]. In the United States (US), the
number of bariatric surgeries amounted to 179,000 in 2013 withSt Mary's Hospital, Imperial
th Floor, Salton House, Praed
Saleh).
er Ltd on behalf of IJS Publishing42.1% of procedures being LSGs while Roux-en-Y gastric bypasses
comprised 34.2% of procedures. This now makes LSG the most
commonly performed bariatric procedure in the US [3].
Controversy exists regarding the role of staple line reinforce-
ment in preventing gastric leaks [4e6]. Knapps et al. [7] concluded
that more studies were needed to assess the safety proﬁle of syn-
thetic bioabsorbable reinforcementmaterials in LSG. However, Choi
et al. [8] and Gagner [15] showed a decreased incidence of leaks
when using these materials intraoperatively.
Additionally, long-term outcomes of LSG in general in terms of
weight loss are lacking in the literature. Diamantis et al. [9] showedGroup Ltd. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Major complication rates related to sleeve gastrectomy within
the ﬁrst 30 days post-operatively.
Complication Patients (%)
Staple line leak 0/204 (0%)
Severe vomiting 7/204 (3.4%)
Sleeve stenosis 2/204 (0.9%)
Major bleeding 2/204 (0.9%)
Wound infection 3/204 (1.5%)
Death 0/204 (0%)
Total 14/204 (6.9%)
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up period and only nine studies contained long-term data of pa-
tients at the ﬁve year follow-up period postoperatively. Several
authors have realized this gap in the literature and there are now
more papers in the literature with outcomes of LSG spanning 5
years or more [10,11].
The aims of this study are (1): to present our leak rates from
using staple line reinforcement and (2) to display six year outcomes
of LSG as a procedure in itself in relation to resolution of obesity-
related comorbidities and long-term weight loss.
2. Materials and methods
2.1. Study design and data collection
This is a single-institution, retrospectively reviewed study of
204 consecutive patient case ﬁles who underwent LSG with rein-
forcement between December 2007 and May 2013. The data was
collected from clinic letters, electronic records and telephone
consultations representing a six year series.
Resolution of obesity-related comorbidities (obstructive sleep
apnea, diabetes, hypertension, hypercholesterolemia) was noted.
Percent excess weight loss (% EWL) and percent excess BMI loss (%
EBL) was calculated at each year postoperatively using the ideal
body weight estimate with a Body Mass Index (BMI) of 25 as the
reference point for normal weight.
Hypertensionwas deﬁned by a blood pressure greater than 140/
90 mmHg and its resolution by a normalized blood pressure and
cessation of all blood pressure medications taken preoperatively.
Obstructive sleep apnea was diagnosed by a sleep study (poly-
somnography) and resolution by cessation of the continuous pos-
itive airway pressure machine. Diabetes mellitus type II was
diagnosed by a fasting blood glucose >7.0 mmol/l (126 mg/dL) or
HbA1c > 42 mmol/mol (6 g/dL). Resolution was deﬁned by
normalization of one of these laboratory values and cessation of any
diabetic medications postoperatively. Lastly, hypercholesterolemia
was diagnosed by total blood cholesterol levels >5.2 mmol/l
(200 mg/dL) and resolution by stopping medication.
Major complications such as severe vomiting and sleeve ste-
nosis related to LSG in general within the ﬁrst 30 days post-
operatively were recorded. Leaks from the staple line were also
recorded using the intraoperative leak test.
Patients who had a primary stand-alone LSG without previous
or subsequent weight-loss surgery within the speciﬁed time period
were included in the study. All patients consented to the collection
of data. The study was submitted as an ofﬁcial audit to the insti-
tutional review board for ethical approval and registration.
2.2. Materials
The GORE® SEAMGUARD® bioabsorbable staple line reinforce-
mentmaterial (W. L. Gore& Associates, Arizona, USA) has been used
at our institution throughout all LSG cases since 2007. The material
adds a reinforcement strip to the staple line, which is preloaded
onto the stapler, and is eventually absorbed within six months [12].
2.3. Surgical technique
The patient is placed on the operating table in the supine po-
sition. The abdominal cavity is entered through a small, transverse
left subcostal incisionwith the bladeless 12 mm trocar, loaded with
the 10-mm O-degree laparoscope, and under laparoscopic
observation.
The blunt tip retractor is placed below the xiphoid process to
retract the left lobe of the liver exposing the gastro-esophagealjunction. The lesser sac is entered through the gastrosplenic liga-
ment and the greater curvature of the stomach is freed up to the
angle of His. Next, a bougie is passed into the distal stomach and the
endostapler loaded with the reinforcement strips is introduced ﬁrst
from the right upper quadrant port to carry out the sleeve gas-
trectomy. The bougie size used for all operations was 32F. Themean
proximal distance from the pylorus used for all operations was 5 cm
(standard deviation of 0.69 cm). A mean total of 5 staple ﬁrings
(standard deviation of 1.04 ﬁrings) preloaded with the bio-
absorbable material were used for all procedures.
2.4. Statistical analysis
The data were analysed with GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA). Continuous data points are presented
as mean ± standard deviation, mean (range), and analysed using
the two-tailed paired t-test. Statistical signiﬁcance was deﬁned at a
p-value of <0.05.
3. Results
3.1. Patient characteristics
Of a total of 257 patients who had undergone an LSG operation
with reinforcement between December 2007 and May 2013, 204
patients (80%) met the inclusion and exclusion criteria. There were
61males and 143 females. Of the 21/53 patientswhowere excluded:
16 patients had previously attempted bariatric procedures and 5
patients had subsequent bariatric surgery due to unsatisfactory
weight loss. 32/53 patients have also been excluded since they were
performed using a different type of staple line reinforcement (Duet
TRS by Covidien). These products have been terminated due to
major complications associated with their use [13].
3.2. Complication rates, morbidity and mortality
The complications experienced in this study were grouped ac-
cording to the Clavien-Dindo classiﬁcation [14]. There were nine
Grade I complications (vomiting resolved by antiemetics and sleeve
stenoses), three Grade II complications (wound infection requiring
antibiotics) and two Grade III complications (major bleeding
requiring surgical intervention) (complications displayed in
Table 1). The intraoperative leak test was used to determine any
potential gastric leaks from the staple line.
In terms of bleeding, there were 2 in the series. The ﬁrst was
taken back to theatre 8 h postoperatively due to tachycardia and a
low blood pressure. In theatre, 1.8 litres of clot was seen in left
upper quadrant which was removed. No obvious bleeding source
was found and the staple lines were dry. The patent was discharged
3 days after the operation.
The second patient had an uneventful postoperative course and
was discharged 2 days after the operation. However, this patient
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generalised abdominal pain. A Computed Tomography (CT) scan
revealed an intra-abdominal haematoma and the patient was taken
to theatre for evacuation of 600 ml of clot. No bleeding source was
found and the staple lines were dry. The patient was discharged 3
days later.
There was a statistically signiﬁcant difference (p < 0.05) be-
tween pre- and post-operative hemoglobin. The mean hemoglobin
was 13.6 g/dL (SD 1.3; Range 9.4e17.3) pre-operatively, dropping to
12.6 g/dL (SD 1.3; Range 8.7e15.8) post-operatively at day 1.
3.3. Weight loss in the short-, mid-, and long-term
Completed weights recorded during each yearly follow-up
period are as follows: 148/204 (73%) in the one year period, 128/
173 (74%) in the two year period, 81/116 (70%) in the three year
period, 49/69 (71%) in the four year period, 24/35 (69%) in the ﬁve
year period, and 5/8 (63%) in the six year period. Reasons for the
remaining incomplete data are due to patients not answering their
telephone, incomplete patient notes and undocumented weights in
clinic letters.
The mean %EWL was used to see if there were statistically sig-
niﬁcant differences in weight gain/loss between follow-ups at year
one (short-term) and three (mid-term), and between year three
and six (long-term). There were no signiﬁcant differences between
follow-ups at year one and three (48.4 ± 18.5 at year 1 vs.
51.7 ± 27.9 at year 3; p > 0.05), and between year three and six
(51.7 ± 27.9 at year 3 vs. 41.0 ± 20.5 at year 6; p > 0.05) in terms of
the mean %EWL (Fig. 1). All results are detailed in Table 2.
3.4. Resolution of obesity-related comorbidities
There were high resolution rates for obesity-related comorbid-
ities: 74% (76/103) of patients with hypertension, 61% (20/33) of
patients with hypercholesterolemia, 79% (34/43) of patients with
diabetes mellitus type 2, and 90% (54/60) of patients with
obstructive sleep apnea.
4. Discussion
4.1. Complication rates for staple line reinforcement materials
Generally, a low rate of total complications after LSG in general1 yr 3 yr s 6 yr s
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Fig. 1. Mean % Excess Weight Loss (EWL) change over the short-, mid-, and long-term
periods of follow-up. No statistical signiﬁcance was found. The 2-tailed, paired t-test
was used. Error bars represent standard deviation. The numbers above the points are
the mean %EWL ± SD.has been observed ranging from 3.2% to 14.3% with mortality
ranging from 0% to 3.3% [15,16]. This compares with our own
experience (total complication rate at 6.9% andmortality rate at 0%).
In terms of leak rates, which may or may not be inﬂuenced by
the use of staple line reinforcement material, our study had no
leaks. Recently, Gagner et al. produced a systematic review that
showed leak rates ranged from 1.09% using bioabsorbable material
to 3.3% using non-absorbable material with the total leak rate at
2.1% (n ¼ 191). The leak rate in LSG was signiﬁcantly lower using
bioabsorbable staple-line reinforcement than oversewing, non-
absorbable material reinforcement, or no reinforcement [17].
In one of the largest studies of LSG to date encompassing 9991
patients, Parikh et al. conducted a meta-analysis of 112 papers. In
6578 LSG patients, the leak rate was 2.1% (n ¼ 102/4780) when
reinforcement was applied and 3.2% (n ¼ 37/1143) when no rein-
forcement was used. However, the authors concluded that rein-
forcement does not seem to impact leak rates signiﬁcantly and that
bioabsorbable materials are the most common type used should
surgeons want to use reinforcement [18]. Similarly, a meta-analysis
of 56,309 patients by Shikora showed that staple line reinforcement
with bovine pericardium had the lowest leak rates (2.45%) when
compared to buttressing with a biocompatible material (2.61%) and
no staple line reinforcement (2.75%) [19].
This important meta-analysis also highlighted the fact that the
majority of papers were very small case series that included under
100 patients. Additionally, over half of patients in the staple line
reinforcement group in Parikh et al.'s study included biocompatible
glycolide copolymer buttresses with either Seamguard (akin to the
material used in our study) or Duet. Duet is nowwithdrawn from the
market making any potential widespread use impossible. Finally, the
study consisted of papers up until 2011 only. Staple line reinforce-
ment in LSG in terms of popularity and volume load has signiﬁcantly
increased since then, warranting an updated meta-analysis.
The beneﬁts of using staple line reinforcement remain contro-
versial. Several authors have questioned whether the low total
complication rate and gastric leak rate seen is due to the use of the
material or due to the expertise of the center or surgeon [7,20,21]. A
recent survey of expert LSG surgeons showed that 100% of re-
spondents agreed that reinforcement decreased leak rates. How-
ever, approximately 20% actually used staple line reinforcement
with a bioabsorbable material in their practices. The difference be-
tween the actual use of reinforcement and agreement in its use
could perhaps be owed to the perceived paucity of published studies
establishing a good safety proﬁle in these materials [22]. In the only
prospective RCT comparing bioabsorbable staple line reinforcement
(SLR) versus suturing versus no SLR, leak rates were lower with SLR
usage. However, the study was underpowered to detect any differ-
ence in leak rates in the 3 groups [21]. It will be interesting to see if
future RCTs will be conducted to study this further.
In terms of major bleeds, there were two patients enduring
signiﬁcant bleeding postoperatively. These bleeds at the time of re-
laparoscopy for clot evacuation had stopped and the reinforced
staple lines were dry. Possible explanations for the mean drop in
hemoglobin include intraoperative bleeding during excision along
the greater curvature of the stomach, the hemodilutional effects of
intraoperative ﬂuids, and/or a rise in ADH in response to the
stresses of surgery.
4.2. Resolution of obesity-related comorbidities
The total resolution rate for hypertension in this series was 74%,
which is very similar to the mean resolution rate of 75.9% found by
Braghetto et al. in his review of long-term outcomes of LSG [23].
Similarly, resolution rates for diabetes mellitus type 2 vary. The
mean resolution rate found in the same review was 78.9% [23],
Table 2
Mean BMI, mean %EBL, mean %EWL, mean %TBWL at different yearly follow-up intervals.
Pre-operative (n ¼ 204) 1 year (n ¼ 148/204) 2 years (n ¼ 128/173) 3 years (n ¼ 81/116) 4 years (n ¼ 49/69) 5 years (n ¼ 24/35) 6 years (n ¼ 5/8)
Primary LSG
Mean BMI (kg/m2) 50.9 39.3 38.7 40.4 40.5 43.0 42.4
SD (kg/m2) 9.9 7.6 8.1 9.2 10.2 9.5 7.0
Range (kg/m2) 32e104.4 22e67 19e72 18e76 21e74 26e60 36e54
Mean %EBL e 48.5 52.1 50.2 50.6 40.0 40.9
SD (%) e 18.5 21.9 24.4 26.1 21.8 20.5
Range (%) e 15e123 6e143 3e151 22e128 12e98 18e61
Mean %EWL e 48.4 53.0 51.7 53.1 40.0 41.0
SD (%) e 18.5 24.4 27.9 31.3 21.8 20.5
Range (%) e 15e122 6e176 3e176 22e176 12e98 18e61
Mean %TBWL e 23.4 25.4 25.2 25.2 20.6 22.5
SD (%) e 8.0 9.2 10.0 11.3 11.5 12.0
Range (%) e 8e47 3e52 2e55 12e58 7e56 8e35
BMI ¼ Body Mass Index; EBL ¼ Excess BMI Loss; EWL ¼ Excess Weight Loss; SD ¼ Standard Deviation; TBWL ¼ Total Body Weight Loss.
M. Saleh et al. / Annals of Medicine and Surgery 10 (2016) 83e8786compared to the 79% in this study. For obstructive sleep apnea,
resolution rates are generally quite high with a 90% resolution rate
shown in this study.
Underlying mechanisms of LSG on the resolution of obesity-
related comorbidities exist. It is difﬁcult to compare our resolu-
tion rates to that of the literature. Different deﬁnitions of diagnosis
of comorbidities were used across studies, which can inﬂuence
resolution rates.
4.3. Long-term weight loss after LSG
Literature reporting on weight loss in the long-term (greater
than ﬁve years) remains scarce, therefore weight loss reported in
this study serves to consolidate the currently limited published
results. The reported ﬁve year %EWL varies in several papers,
ranging from 49.5% to 86% [23e29], and from 52% to 53.3%
[23,30,31] in six years. Similarly, our ﬁve year mean %EWL was 40%
and the six year mean %EWL was 41%. Even so, it is difﬁcult to
compare weight loss results across different studies since different
bougie sizes were used to create the sleeve. Smaller bougie sizes
may result in tighter sleeves, therefore reducing gastric capacity
and food intake [32].
We expected that weight loss begins immediately after surgery
and remains signiﬁcantly lower than what it was preoperatively.
There were no statistically signiﬁcant differences between year 1
and year 3, and year 3 and year 6 postoperatively. However, the
small number of recordedweights in the six year group (n¼ 5) may
render the year 3 and year 6 comparison for possible weight regain
unreliable. The trend for mean %EWL and mean %EBL seems to
show that patients maintain their weight loss postoperatively and
lose even more weight between year one and year three post-
operatively. However, some weight regain occurred between year
three and year six postoperatively. Weight loss in the short-to mid-
term period may partly be explained by suppression of ghrelin (a
hunger-stimulating hormone) obtained by the resection of the
gastric fundus in LSG. However, in the mid-to long-term period
postoperatively, hyperactivity of previously silent ghrelin-
producing cells may cancel the early effect of fundic resection
[33]. Late weight regain can be caused by dietary factors as well,
such as changes in eating behaviour by moving towards ingesting
highly caloric food. Dietary causes may be detected and can
potentially be avoided by continuous follow-up appointments
aiming at reinforcing patient education and motivation.
4.4. Limitations
There are several limitations. As this is a retrospective review ofpatients, attrition rateswere an important problem. In this study, the
attrition rate was highest, at 37%, in patients with recorded weights
at the six year follow-up period. This could be attributed to various
factors including patient non-compliance to completing their
follow-up appointments and may inﬂuence long term weight loss
outcomes had all patients been analysed for their recorded weights.
Telephone consultations used in obtaining additional informa-
tion to clinic lettersmay present its ownproblems. According to our
experiences, telephone consultations are generally considered
biased in the sense that patients may underestimate their weight.
Therefore, the true ﬁnal BMI could be even higher than the ones
reported in this study.
The documented post sleeve complication rates are free of the
limitations mentioned above especially as bleeds and leaks tend to
occur in the early postoperative phase. Therefore these complica-
tions would have all been captured and our complication rates are
true and were achieved.
Additionally, it is important to mention that this study received
industry funding. Probst et al. have recently shown that industry
bias in surgical research is more likely to be associatedwith positive
ﬁndings and signiﬁcant results [34]. Although this study has shown
low complication rates with regards to using the reinforcement
material and good long-term outcomes in LSG, our ﬁndings have
been replicated in other studies that have not received industry
funding.
Finally, this study is a retrospective study with no comparator
cohort of patients undertaking LSG without staple line reinforce-
ment. The true beneﬁt of staple line reinforcement versus no rein-
forcement can not be commented on although this study serves to
show that the use of the GORE® Seamguard was safe to use pre-
senting with no staple line leaks.
5. Conclusion
The GORE® Seamguard material used in this study is safe to use
in terms of low complication rates. To effectively elucidate a beneﬁt
in using bioabsorbable materials to reinforce the staple line, pro-
spective randomized controlled trials are recommended. LSG also
shows good long-term weight loss as well as high resolution rates
of obesity related comorbidities. These results add to the currently
lacking literature in terms of long-term outcomes in LSG.
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